Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial

Myung Chul Yoo; Wan Hee Yoo; Seung Baek Kang; Yong Wook Park; Sung Soo Kim; Kyoung Ho Moon; Yeong Wook Song; Byung Woo Min; Yoon Je Cho; Seong Hwan Moon; Seong Il Bin; Han Joo Baek; Seung Cheol Shim; Sung Won Lee; Dae Hyun Yoo; Anish Mehta; Aleksandar Skuban; Diane M. Cukrow; Kristel Vandormael; Li Yan

doi:10.1185/03007995.2014.955169

Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial

Myung Chul Yoo, Wan Hee Yoo, Seung Baek Kang, Yong Wook Park, Sung Soo Kim, Kyoung Ho Moon, Yeong Wook Song, Byung Woo Min, Yoon Je Cho, Seong Hwan Moon, Seong Il Bin, Han Joo Baek, Seung Cheol Shim, Sung Won Lee, Dae Hyun Yoo, Anish Mehta, Aleksandar Skuban, Diane M. Cukrow, Kristel Vandormael, Li Yan

Department of Orthopaedic Surgery

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Objective: We evaluated the COX-2 inhibitors, etoricoxib and celecoxib, in Korean patients with osteoarthritis (OA).

Methods: This study included patients (≥40 years of age) with a clinical and radiographic diagnosis of knee OA. Patients were randomized to etoricoxib 30 mg (qd) or celecoxib 200 mg (qd) in a 12 week randomized, controlled, double-blind study. Prior NSAID users were to demonstrate a worsening of symptoms upon withdrawal of medication. Efficacy endpoints included the time-weighted average change from baseline in the WOMAC VA 3.0 Pain Subscale (100mm Visual Analog Scale [VAS]; primary endpoint), the WOMAC VA 3.0 Physical Function Subscale (100mm VAS), and Patient Global Assessment of Disease Status (PGAD) (100mm VAS). The primary hypothesis was that etoricoxib 30 mg is non-inferior to celecoxib 200 mg as assessed by the primary endpoint (the non-inferiority margin was set at 10mm VAS). Adverse events (AEs), laboratory parameters, and vital signs were monitored.

Results: There were 239 patients (89.5% female; mean age: 63.3 years) randomized to etoricoxib 30 mg (n=120) and celecoxib 200 mg (n=119). The differences (etoricoxib vs celecoxib) in least square (LS) mean change (95% CI) for WOMAC Pain, WOMAC Physical Function, and PGAD were -1.63 mm (-5.37, 2.10), -1.32mm (-4.88, 2.23), and -1.09 mm (-5.48, 3.30), respectively. Drug-related clinical AEs occurred in 6.7% (etoricoxib) and 2.5% (celecoxib) of patients. This study was limited because it was not designed or powered to adequately capture and evaluate rare AEs associated with NSAID treatment.

Conclusions: Etoricoxib 30 mg administered once daily in Korean patients with knee OA demonstrated non-inferior clinical efficacy to celecoxib 200 mg over 12 weeks of treatment as assessed by all primary and secondary outcomes. Etoricoxib 30 mg qd and celecoxib 200 mg qd were generally safe and well tolerated.

Clinical trial registration: NCT01554163.

Original language	English
Pages (from-to)	2399-2408
Number of pages	10
Journal	Current Medical Research and Opinion
Volume	30
Issue number	12
DOIs	https://doi.org/10.1185/03007995.2014.955169
Publication status	Published - 2014 Dec 1

Bibliographical note

Funding Information:
A.M., A.S., D.M.C., K.V., and L.Y. have disclosed that they are current or former employees of Merck & Co. Inc., the sponsor of this study. Y.J.C. has disclosed that she/he has received research grants from MSD Korea. D.H.Y. has disclosed that she/he has received research grants and consulting and speakers’ fees from Celltrion. M.C.Y., W.H.Y., S.B.K., Y.-W.P., S.S.K., K.H.M., Y.W.S., B.W.M., S.-H.M., S.-I.B., H.-J.B., S.C.S., and S.W.L. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article.

Funding Information:
This study was funded by Merck & Co. Inc., Whitehouse Station, NJ, USA.

Publisher Copyright:
© 2014 All rights reserved: reproduction in whole or part not permitted.

All Science Journal Classification (ASJC) codes

Medicine(all)

Access to Document

10.1185/03007995.2014.955169

Cite this

Yoo, M. C., Yoo, W. H., Kang, S. B., Park, Y. W., Kim, S. S., Moon, K. H., Song, Y. W., Min, B. W., Cho, Y. J., Moon, S. H., Bin, S. I., Baek, H. J., Shim, S. C., Lee, S. W., Yoo, D. H., Mehta, A., Skuban, A., Cukrow, D. M., Vandormael, K., & Yan, L. (2014). Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial. Current Medical Research and Opinion, 30(12), 2399-2408. https://doi.org/10.1185/03007995.2014.955169

@article{73676d8728fb46f593eccf74b4e27582,

title = "Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial",

abstract = "Objective: We evaluated the COX-2 inhibitors, etoricoxib and celecoxib, in Korean patients with osteoarthritis (OA).Methods: This study included patients (≥40 years of age) with a clinical and radiographic diagnosis of knee OA. Patients were randomized to etoricoxib 30 mg (qd) or celecoxib 200 mg (qd) in a 12 week randomized, controlled, double-blind study. Prior NSAID users were to demonstrate a worsening of symptoms upon withdrawal of medication. Efficacy endpoints included the time-weighted average change from baseline in the WOMAC VA 3.0 Pain Subscale (100mm Visual Analog Scale [VAS]; primary endpoint), the WOMAC VA 3.0 Physical Function Subscale (100mm VAS), and Patient Global Assessment of Disease Status (PGAD) (100mm VAS). The primary hypothesis was that etoricoxib 30 mg is non-inferior to celecoxib 200 mg as assessed by the primary endpoint (the non-inferiority margin was set at 10mm VAS). Adverse events (AEs), laboratory parameters, and vital signs were monitored.Results: There were 239 patients (89.5% female; mean age: 63.3 years) randomized to etoricoxib 30 mg (n=120) and celecoxib 200 mg (n=119). The differences (etoricoxib vs celecoxib) in least square (LS) mean change (95% CI) for WOMAC Pain, WOMAC Physical Function, and PGAD were -1.63 mm (-5.37, 2.10), -1.32mm (-4.88, 2.23), and -1.09 mm (-5.48, 3.30), respectively. Drug-related clinical AEs occurred in 6.7% (etoricoxib) and 2.5% (celecoxib) of patients. This study was limited because it was not designed or powered to adequately capture and evaluate rare AEs associated with NSAID treatment.Conclusions: Etoricoxib 30 mg administered once daily in Korean patients with knee OA demonstrated non-inferior clinical efficacy to celecoxib 200 mg over 12 weeks of treatment as assessed by all primary and secondary outcomes. Etoricoxib 30 mg qd and celecoxib 200 mg qd were generally safe and well tolerated.Clinical trial registration: NCT01554163.",

author = "Yoo, {Myung Chul} and Yoo, {Wan Hee} and Kang, {Seung Baek} and Park, {Yong Wook} and Kim, {Sung Soo} and Moon, {Kyoung Ho} and Song, {Yeong Wook} and Min, {Byung Woo} and Cho, {Yoon Je} and Moon, {Seong Hwan} and Bin, {Seong Il} and Baek, {Han Joo} and Shim, {Seung Cheol} and Lee, {Sung Won} and Yoo, {Dae Hyun} and Anish Mehta and Aleksandar Skuban and Cukrow, {Diane M.} and Kristel Vandormael and Li Yan",

note = "Funding Information: A.M., A.S., D.M.C., K.V., and L.Y. have disclosed that they are current or former employees of Merck & Co. Inc., the sponsor of this study. Y.J.C. has disclosed that she/he has received research grants from MSD Korea. D.H.Y. has disclosed that she/he has received research grants and consulting and speakers{\textquoteright} fees from Celltrion. M.C.Y., W.H.Y., S.B.K., Y.-W.P., S.S.K., K.H.M., Y.W.S., B.W.M., S.-H.M., S.-I.B., H.-J.B., S.C.S., and S.W.L. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article. Funding Information: This study was funded by Merck & Co. Inc., Whitehouse Station, NJ, USA. Publisher Copyright: {\textcopyright} 2014 All rights reserved: reproduction in whole or part not permitted.",

year = "2014",

month = dec,

day = "1",

doi = "10.1185/03007995.2014.955169",

language = "English",

volume = "30",

pages = "2399--2408",

journal = "Current Medical Research and Opinion",

issn = "0300-7995",

publisher = "Informa Healthcare",

number = "12",

}

Yoo, MC, Yoo, WH, Kang, SB, Park, YW, Kim, SS, Moon, KH, Song, YW, Min, BW, Cho, YJ, Moon, SH, Bin, SI, Baek, HJ, Shim, SC, Lee, SW, Yoo, DH, Mehta, A, Skuban, A, Cukrow, DM, Vandormael, K & Yan, L 2014, 'Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial', Current Medical Research and Opinion, vol. 30, no. 12, pp. 2399-2408. https://doi.org/10.1185/03007995.2014.955169

TY - JOUR

T1 - Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial

AU - Yoo, Myung Chul

AU - Yoo, Wan Hee

AU - Kang, Seung Baek

AU - Park, Yong Wook

AU - Kim, Sung Soo

AU - Moon, Kyoung Ho

AU - Song, Yeong Wook

AU - Min, Byung Woo

AU - Cho, Yoon Je

AU - Moon, Seong Hwan

AU - Bin, Seong Il

AU - Baek, Han Joo

AU - Shim, Seung Cheol

AU - Lee, Sung Won

AU - Yoo, Dae Hyun

AU - Mehta, Anish

AU - Skuban, Aleksandar

AU - Cukrow, Diane M.

AU - Vandormael, Kristel

AU - Yan, Li

N1 - Funding Information: A.M., A.S., D.M.C., K.V., and L.Y. have disclosed that they are current or former employees of Merck & Co. Inc., the sponsor of this study. Y.J.C. has disclosed that she/he has received research grants from MSD Korea. D.H.Y. has disclosed that she/he has received research grants and consulting and speakers’ fees from Celltrion. M.C.Y., W.H.Y., S.B.K., Y.-W.P., S.S.K., K.H.M., Y.W.S., B.W.M., S.-H.M., S.-I.B., H.-J.B., S.C.S., and S.W.L. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article. Funding Information: This study was funded by Merck & Co. Inc., Whitehouse Station, NJ, USA. Publisher Copyright: © 2014 All rights reserved: reproduction in whole or part not permitted.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Objective: We evaluated the COX-2 inhibitors, etoricoxib and celecoxib, in Korean patients with osteoarthritis (OA).Methods: This study included patients (≥40 years of age) with a clinical and radiographic diagnosis of knee OA. Patients were randomized to etoricoxib 30 mg (qd) or celecoxib 200 mg (qd) in a 12 week randomized, controlled, double-blind study. Prior NSAID users were to demonstrate a worsening of symptoms upon withdrawal of medication. Efficacy endpoints included the time-weighted average change from baseline in the WOMAC VA 3.0 Pain Subscale (100mm Visual Analog Scale [VAS]; primary endpoint), the WOMAC VA 3.0 Physical Function Subscale (100mm VAS), and Patient Global Assessment of Disease Status (PGAD) (100mm VAS). The primary hypothesis was that etoricoxib 30 mg is non-inferior to celecoxib 200 mg as assessed by the primary endpoint (the non-inferiority margin was set at 10mm VAS). Adverse events (AEs), laboratory parameters, and vital signs were monitored.Results: There were 239 patients (89.5% female; mean age: 63.3 years) randomized to etoricoxib 30 mg (n=120) and celecoxib 200 mg (n=119). The differences (etoricoxib vs celecoxib) in least square (LS) mean change (95% CI) for WOMAC Pain, WOMAC Physical Function, and PGAD were -1.63 mm (-5.37, 2.10), -1.32mm (-4.88, 2.23), and -1.09 mm (-5.48, 3.30), respectively. Drug-related clinical AEs occurred in 6.7% (etoricoxib) and 2.5% (celecoxib) of patients. This study was limited because it was not designed or powered to adequately capture and evaluate rare AEs associated with NSAID treatment.Conclusions: Etoricoxib 30 mg administered once daily in Korean patients with knee OA demonstrated non-inferior clinical efficacy to celecoxib 200 mg over 12 weeks of treatment as assessed by all primary and secondary outcomes. Etoricoxib 30 mg qd and celecoxib 200 mg qd were generally safe and well tolerated.Clinical trial registration: NCT01554163.

AB - Objective: We evaluated the COX-2 inhibitors, etoricoxib and celecoxib, in Korean patients with osteoarthritis (OA).Methods: This study included patients (≥40 years of age) with a clinical and radiographic diagnosis of knee OA. Patients were randomized to etoricoxib 30 mg (qd) or celecoxib 200 mg (qd) in a 12 week randomized, controlled, double-blind study. Prior NSAID users were to demonstrate a worsening of symptoms upon withdrawal of medication. Efficacy endpoints included the time-weighted average change from baseline in the WOMAC VA 3.0 Pain Subscale (100mm Visual Analog Scale [VAS]; primary endpoint), the WOMAC VA 3.0 Physical Function Subscale (100mm VAS), and Patient Global Assessment of Disease Status (PGAD) (100mm VAS). The primary hypothesis was that etoricoxib 30 mg is non-inferior to celecoxib 200 mg as assessed by the primary endpoint (the non-inferiority margin was set at 10mm VAS). Adverse events (AEs), laboratory parameters, and vital signs were monitored.Results: There were 239 patients (89.5% female; mean age: 63.3 years) randomized to etoricoxib 30 mg (n=120) and celecoxib 200 mg (n=119). The differences (etoricoxib vs celecoxib) in least square (LS) mean change (95% CI) for WOMAC Pain, WOMAC Physical Function, and PGAD were -1.63 mm (-5.37, 2.10), -1.32mm (-4.88, 2.23), and -1.09 mm (-5.48, 3.30), respectively. Drug-related clinical AEs occurred in 6.7% (etoricoxib) and 2.5% (celecoxib) of patients. This study was limited because it was not designed or powered to adequately capture and evaluate rare AEs associated with NSAID treatment.Conclusions: Etoricoxib 30 mg administered once daily in Korean patients with knee OA demonstrated non-inferior clinical efficacy to celecoxib 200 mg over 12 weeks of treatment as assessed by all primary and secondary outcomes. Etoricoxib 30 mg qd and celecoxib 200 mg qd were generally safe and well tolerated.Clinical trial registration: NCT01554163.

UR - http://www.scopus.com/inward/record.url?scp=84914105208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914105208&partnerID=8YFLogxK

U2 - 10.1185/03007995.2014.955169

DO - 10.1185/03007995.2014.955169

M3 - Article

C2 - 25133963

AN - SCOPUS:84914105208

SN - 0300-7995

VL - 30

SP - 2399

EP - 2408

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

IS - 12

ER -

Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this